STOCK TITAN
  1. Home
  2. Sec-filings
  3. RYTM
  4. [Form 4] Rhythm Pharmaceuticals, Inc. Insider Trading Activity

Rhythm Pharmaceuticals Boosts Director Compensation with Options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Rhythm Pharmaceuticals director Jennifer L. Good received new equity compensation grants on June 24, 2025, consisting of:

  • 7,037 stock options with an exercise price of $63.66 per share, expiring June 23, 2035
  • 4,712 restricted stock units (RSUs), each convertible into one share of common stock

Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options and RSUs were granted at $0 cost to the director. This appears to be part of the company's regular annual director compensation program. The filing was submitted by Stephen Vander Stoep as attorney-in-fact for Jennifer Good.

Positive

  • None.

Negative

  • None.
Insider GOOD JENNIFER L
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 7,037 $0.00 --
Grant/Award Restricted Stock Units 4,712 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 7,037 shares (Direct); Restricted Stock Units — 4,712 shares (Direct)
Footnotes (1)
  1. The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOOD JENNIFER L
(Last) (First) (Middle)
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR
(Street)
BOSTON MA 02116
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $63.66 06/24/2025 A 7,037 (1) 06/23/2035 Common Stock 7,037 $0 7,037 D
Restricted Stock Units (2) 06/24/2025 A 4,712 (3) (3) Common Stock 4,712 $0 4,712 D
Explanation of Responses:
1. The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.
2. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
3. The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
/s/ Stephen Vander Stoep, attorney-in-fact for Jennifer L. Good 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What stock options did RYTM director Jennifer Good receive in June 2025?

Jennifer Good received stock options to buy 7,037 shares of RYTM common stock at an exercise price of $63.66 per share. These options were granted on June 24, 2025 and will expire on June 23, 2035.

When do Jennifer Good's RYTM stock options and RSUs vest?

Both the stock options and restricted stock units (RSUs) will fully vest upon the earlier of: (i) June 24, 2026 or (ii) the day immediately prior to RYTM's 2026 annual stockholder meeting, subject to Good's continued service through the vesting date.

How many restricted stock units (RSUs) were granted to RYTM director Jennifer Good?

Jennifer Good was granted 4,712 restricted stock units (RSUs) on June 24, 2025. Each RSU represents a contingent right to receive one share of RYTM common stock upon vesting.

What is the total value of RYTM equity compensation granted to Jennifer Good in June 2025?

The Form 4 shows Jennifer Good received two equity grants on June 24, 2025: (1) options to purchase 7,037 shares at $63.66 per share, and (2) 4,712 restricted stock units. Both were granted at $0 cost to the director but represent future rights to RYTM common stock subject to vesting conditions.